WO2011117378A3 - Compositions comprising brimonidine for the treatment of erythema - Google Patents
Compositions comprising brimonidine for the treatment of erythema Download PDFInfo
- Publication number
- WO2011117378A3 WO2011117378A3 PCT/EP2011/054597 EP2011054597W WO2011117378A3 WO 2011117378 A3 WO2011117378 A3 WO 2011117378A3 EP 2011054597 W EP2011054597 W EP 2011054597W WO 2011117378 A3 WO2011117378 A3 WO 2011117378A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brimonidine
- compositions
- treatment
- erythema
- telangiectasia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/636,463 US8916562B2 (en) | 2010-03-26 | 2011-03-25 | Methods and compositions for safe and effective treatment of telangiectasia |
BR112012024476A BR112012024476A2 (en) | 2010-03-26 | 2011-03-25 | method for providing safe and effective treatment of telangiectasia and method of producing a packaged product |
KR1020127027975A KR20130010122A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
CA2792649A CA2792649A1 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
RU2012145614/15A RU2535008C2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
CN2011800260323A CN103096894A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
ES11709960T ES2730411T3 (en) | 2010-03-26 | 2011-03-25 | Enhanced compositions comprising brimonidine for a safe and effective treatment of telangiectasia |
JP2013500521A JP5747392B2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
AU2011231544A AU2011231544B2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
MX2012010823A MX2012010823A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia. |
KR1020157012187A KR20150058551A (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
EP11709960.6A EP2552448B1 (en) | 2010-03-26 | 2011-03-25 | Improved compositions comprising brimonidine for safe and effective treatment of telangiectasia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28275310P | 2010-03-26 | 2010-03-26 | |
US61/282,753 | 2010-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011117378A2 WO2011117378A2 (en) | 2011-09-29 |
WO2011117378A3 true WO2011117378A3 (en) | 2012-12-20 |
Family
ID=44022964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/054597 WO2011117378A2 (en) | 2010-03-26 | 2011-03-25 | Improved methods and compositions for safe and effective treatment of telangiectasia |
Country Status (12)
Country | Link |
---|---|
US (1) | US8916562B2 (en) |
EP (1) | EP2552448B1 (en) |
JP (1) | JP5747392B2 (en) |
KR (2) | KR20130010122A (en) |
CN (1) | CN103096894A (en) |
AU (1) | AU2011231544B2 (en) |
BR (1) | BR112012024476A2 (en) |
CA (1) | CA2792649A1 (en) |
ES (1) | ES2730411T3 (en) |
MX (1) | MX2012010823A (en) |
RU (1) | RU2535008C2 (en) |
WO (1) | WO2011117378A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
EP2552449B1 (en) | 2010-03-26 | 2017-04-19 | Galderma Research & Development | Compositions comprising brimonidine for the treatment of erythema |
AR083651A1 (en) | 2010-10-21 | 2013-03-13 | Galderma Sa | BRIMONIDINE COMPOSITIONS IN GEL AND METHODS OF USE |
UA109359C2 (en) * | 2011-11-10 | 2015-08-10 | TREATMENT OF SKIN DISEASES AND STATES | |
US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
WO2015013709A2 (en) * | 2013-07-26 | 2015-01-29 | Galderma Research & Development | Method for treating skin thickening |
CN104666239A (en) * | 2013-11-27 | 2015-06-03 | 杭州赛利药物研究所有限公司 | Brimonidine tartrate gel and preparation method thereof |
US10744135B2 (en) * | 2016-06-28 | 2020-08-18 | Doris Maria HEXSEL | Use of an active substance in the treatment of melasma |
RU2766973C1 (en) * | 2021-10-05 | 2022-03-16 | Татьяна Сергеевна Русина | Method for combination therapy for rosacea of erithematous-teleangectatic subtype |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060233860A1 (en) * | 2004-04-30 | 2006-10-19 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20060264515A1 (en) * | 2003-05-27 | 2006-11-23 | Sansrosa Pharmaceutical Developments, Inc. | Compounds, formulations, and methods for ameliorating telangiectasias |
US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
WO2009082452A1 (en) * | 2007-12-21 | 2009-07-02 | Dejovin Jack A | Pre-surgical treatment |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
US3560501A (en) | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
BG16042A3 (en) | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
US3594380A (en) | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
BE766039A (en) | 1971-04-21 | 1971-09-16 | Labofina Sa | NEW POLYMERS CONTAINING PYRAZOLE UNITS AND PROCESS FOR PREPARING THESE POLYMERS. |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
BE795970A (en) | 1972-02-29 | 1973-08-27 | Pfizer | NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM |
US4164570A (en) | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4285967A (en) | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
US4256763A (en) | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
US5166331A (en) | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
FR2648709A1 (en) | 1989-06-23 | 1990-12-28 | Boehringer Ingelheim France | NOVEL USE OF 1-PHENYL-2-AMINOETHANOL DERIVATIVES AS HEALING MEANS |
US5326763A (en) | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5112822A (en) | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5198442A (en) | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
US5204347A (en) | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5130441A (en) | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
US5237072A (en) | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
GB9010526D0 (en) | 1990-05-10 | 1990-07-04 | Unilever Plc | Cosmetic composition |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
US6323204B1 (en) | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
AU688380B2 (en) | 1993-10-13 | 1998-03-12 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
WO1996025163A1 (en) | 1995-02-14 | 1996-08-22 | Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center | Treatment of herpes simplex viruses |
US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5720962A (en) | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
US5753637A (en) | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
JP2001512471A (en) | 1997-02-21 | 2001-08-21 | バイヤースドルフ・アクチエンゲゼルシヤフト | Preparations for the treatment of rosacea |
US6007846A (en) | 1997-05-16 | 1999-12-28 | Townley Jewelry, Inc. | Scented body gel having particulate matter in the form of glitter with predetermined shapes |
US6159944A (en) | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
CA2323451C (en) | 1998-03-11 | 2013-01-08 | Kabushiki Kaisha Soken | Skin conditioner |
US6432934B1 (en) | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
US20030087962A1 (en) | 1998-10-20 | 2003-05-08 | Omeros Corporation | Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation |
US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
WO2000076502A1 (en) | 1999-06-11 | 2000-12-21 | The Ohio State University Research Foundation | Methods and compositions for treating raynaud's phenomenon and scleroderma |
US6147102A (en) | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
US20030077301A1 (en) | 1999-12-16 | 2003-04-24 | Maibach Howard I. | Topical pharmaceutical composition for the treatment of inflammatory dermatoses |
US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US6284765B1 (en) | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
TNSN02063A1 (en) | 2001-07-07 | 2005-12-23 | Egyptian Natural Oil Co Natoil | The medical effect of jojoba oil |
US7115724B2 (en) | 2001-08-22 | 2006-10-03 | Wyeth | Murine genomic polynucleotide sequence encoding a G-protein coupled receptor and methods of use therefor |
US6680062B2 (en) | 2001-10-05 | 2004-01-20 | Color Access, Inc. | Anti-irritating rosacea treatment |
US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7345065B2 (en) | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US20040092482A1 (en) | 2002-11-07 | 2004-05-13 | Gupta Shyam K. | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions |
US20040156873A1 (en) | 2003-02-10 | 2004-08-12 | Gupta Shyam K. | Topically Bioavailable Acne and Rosacea Treatment Compositions |
US20040220259A1 (en) | 2003-04-04 | 2004-11-04 | Yu Ruey J. | Topical treatment of dermatological disorders associated with reactive or dilated blood vessels |
WO2004103233A1 (en) | 2003-05-15 | 2004-12-02 | Cutanix Corporation | Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
NZ545401A (en) * | 2003-09-04 | 2008-10-31 | Merck & Co Inc | Ophthalmic compositions for treating ocular hypertension |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US7812049B2 (en) | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
US20050196418A1 (en) | 2004-03-04 | 2005-09-08 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
PT1761266E (en) | 2004-05-25 | 2013-06-04 | Galderma Pharma Sa | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
US20070003622A1 (en) | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
US7288263B2 (en) | 2004-09-13 | 2007-10-30 | Evera Laboratories, Llc | Compositions and methods for treatment of skin discoloration |
US7709533B2 (en) | 2005-02-01 | 2010-05-04 | Icagen, Inc. | Imines as ion channel modulators |
US20070082070A1 (en) | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
EP1998788A4 (en) | 2006-03-01 | 2011-08-03 | Ruey J Yu | Composition and method for topical treatment of tar-responsive dermatological disorders |
US20070258935A1 (en) | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water dispersible films for delivery of active agents to the epidermis |
JP5850602B2 (en) | 2006-12-21 | 2016-02-03 | サンテン・エス・エー・エス | Process for producing ophthalmic oil-in-water emulsions |
DE102006062619B4 (en) | 2006-12-29 | 2012-04-26 | Medion Diagnostics Ag | Method for the determination of minor cell populations in heterogeneous cell populations |
WO2008144399A1 (en) | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS |
DK2182960T3 (en) | 2007-07-27 | 2014-05-26 | Galderma Lab Inc | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Furrows and Slackness |
JP5670196B2 (en) | 2007-11-16 | 2015-02-18 | バイセプト セラピューティクス、インク. | Compositions and methods for treating purpura |
EP2090307A1 (en) | 2008-02-15 | 2009-08-19 | Bone Therapeutics | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases |
AU2009251743A1 (en) | 2008-05-30 | 2009-12-03 | Fairfield Clinical Trials, Llc | Method and composition for skin inflammation and discoloration |
WO2009158646A1 (en) | 2008-06-27 | 2009-12-30 | Elixir Pharmaceuticals, Inc. | Therapeutic compunds and related methods of use |
US8080550B2 (en) | 2008-08-01 | 2011-12-20 | Alpha Synergy Development, Inc. | Anesthetic compositions and methods of use |
WO2010027349A1 (en) | 2008-09-03 | 2010-03-11 | Transdermal Innovations Inc. | Multipurpose hydrogel compositions and products |
US20100196291A1 (en) | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
JP5052558B2 (en) * | 2009-04-03 | 2012-10-17 | ロート製薬株式会社 | Gel ointment |
CN104324378A (en) | 2009-05-29 | 2015-02-04 | 盖尔德马研究及发展公司 | Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection |
JP2013508454A (en) | 2009-10-26 | 2013-03-07 | ガルデルマ ファルマ ソシエテ アノニム | Treatment or prevention of acute erythema |
US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
EP2552449B1 (en) | 2010-03-26 | 2017-04-19 | Galderma Research & Development | Compositions comprising brimonidine for the treatment of erythema |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2011
- 2011-03-25 US US13/636,463 patent/US8916562B2/en active Active
- 2011-03-25 MX MX2012010823A patent/MX2012010823A/en active IP Right Grant
- 2011-03-25 CA CA2792649A patent/CA2792649A1/en not_active Abandoned
- 2011-03-25 WO PCT/EP2011/054597 patent/WO2011117378A2/en active Application Filing
- 2011-03-25 RU RU2012145614/15A patent/RU2535008C2/en active
- 2011-03-25 ES ES11709960T patent/ES2730411T3/en active Active
- 2011-03-25 JP JP2013500521A patent/JP5747392B2/en not_active Expired - Fee Related
- 2011-03-25 KR KR1020127027975A patent/KR20130010122A/en active Application Filing
- 2011-03-25 EP EP11709960.6A patent/EP2552448B1/en active Active
- 2011-03-25 CN CN2011800260323A patent/CN103096894A/en active Pending
- 2011-03-25 BR BR112012024476A patent/BR112012024476A2/en not_active Application Discontinuation
- 2011-03-25 AU AU2011231544A patent/AU2011231544B2/en not_active Ceased
- 2011-03-25 KR KR1020157012187A patent/KR20150058551A/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060264515A1 (en) * | 2003-05-27 | 2006-11-23 | Sansrosa Pharmaceutical Developments, Inc. | Compounds, formulations, and methods for ameliorating telangiectasias |
US20100021402A1 (en) * | 2003-05-27 | 2010-01-28 | Galderma Laboratories Inc. | Compounds, Formulations, and Methods for Ameliorating Telangiectasis |
US20060233860A1 (en) * | 2004-04-30 | 2006-10-19 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
WO2009082452A1 (en) * | 2007-12-21 | 2009-07-02 | Dejovin Jack A | Pre-surgical treatment |
Also Published As
Publication number | Publication date |
---|---|
AU2011231544B2 (en) | 2015-01-15 |
US20130059857A1 (en) | 2013-03-07 |
EP2552448B1 (en) | 2019-04-24 |
RU2535008C2 (en) | 2014-12-10 |
US8916562B2 (en) | 2014-12-23 |
EP2552448A2 (en) | 2013-02-06 |
CA2792649A1 (en) | 2011-09-29 |
RU2012145614A (en) | 2014-05-10 |
JP2013523612A (en) | 2013-06-17 |
AU2011231544A1 (en) | 2012-09-27 |
KR20150058551A (en) | 2015-05-28 |
CN103096894A (en) | 2013-05-08 |
KR20130010122A (en) | 2013-01-25 |
ES2730411T3 (en) | 2019-11-11 |
JP5747392B2 (en) | 2015-07-15 |
WO2011117378A2 (en) | 2011-09-29 |
BR112012024476A2 (en) | 2017-03-01 |
MX2012010823A (en) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011117377A3 (en) | Compositions comprising brimonidine for the treatment of erythema | |
WO2011117378A3 (en) | Compositions comprising brimonidine for the treatment of erythema | |
WO2012009678A8 (en) | Therapeutically active compositions and their method of use | |
WO2012050831A3 (en) | Combination treatment for dermatological conditions | |
WO2015003360A3 (en) | Therapeutically active compounds and their methods of use | |
WO2012047645A3 (en) | Combination treatment for rosacea | |
WO2011085162A3 (en) | Topical transdermal dexmedetomidine compositions and methods of use thereof | |
IL225632A0 (en) | Topical base and active agent-containing compositions, and methods for improving and treating skin | |
WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
WO2012143497A3 (en) | Novel binder-drug conjugates (adcs) and their use | |
WO2012062925A3 (en) | Compounds and methods for treating pain | |
WO2012143576A3 (en) | Compounds for preventing, reducing and/or alleviating itchy skin condition(s) | |
MX367091B (en) | TOPICAL COMPOSITIONS and METHODS OF USE. | |
WO2015003355A3 (en) | Therapeutically active compounds and their methods of use | |
WO2014043230A3 (en) | Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof | |
MX2015004006A (en) | Topical ketoprofen composition. | |
NZ716033A (en) | Treatment of papulopustular rosacea with ivermectin | |
WO2012071369A3 (en) | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease | |
WO2013180834A3 (en) | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria | |
WO2012052479A3 (en) | Brimonidine gel compositions and methods of use | |
WO2010097788A3 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
WO2011049327A3 (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
EP2575842A4 (en) | A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases | |
WO2014145236A3 (en) | The use of sdf-1 to mitigate scar formation | |
WO2012052478A3 (en) | Topical gel composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180026032.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11709960 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011231544 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2792649 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011709960 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/010823 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2774/KOLNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013500521 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011231544 Country of ref document: AU Date of ref document: 20110325 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127027975 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012145614 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13636463 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012024476 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012024476 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120926 |